Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval. TAE profiles were generated by aggregating AEs from the FD...

Descripción completa

Detalles Bibliográficos
Autores principales: Schotland, Peter, Racz, Rebecca, Jackson, David, Levin, Robert, Strauss, David G., Burkhart, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310867/
https://www.ncbi.nlm.nih.gov/pubmed/30354029
http://dx.doi.org/10.1002/psp4.12356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310867/
https://www.ncbi.nlm.nih.gov/pubmed/30354029
http://dx.doi.org/10.1002/psp4.12356

Ejemplares similares